Cognitive
Agitation in Dementia
search
Agitation in Dementia
, Dementia Related Agitation
See Also
Dementia
Dementia Management
No-fail Environment in Dementia
Dementia Related Malnutrition
Behavior Problems in Dementia
Sleep Problems in Dementia
Wandering Behavior in Dementia
Pathophysiology
As
Dementia
progresses, behavior replaces language as the primary communication medium
Etiology
Behavior Decompensation (The 6 I's)
See
Delirium
Iatrogenic
Anticholinergic Medication
s
Sedative-Hypnotic
Medications
Infection
Urinary Tract Infection
Pneumonia
Injury
Occult
Hip Fracture
or other
Fracture
Pain is a common exacerbating factor
Consider scheduled
Acetaminophen
dosing (e.g. 650 mg orally three times daily)
Illness exacerbation
Diabetes Mellitus
Chronic Obstructive Pulmonary Disease
(
COPD
)
Major Depression
Impaction of feces
Inconsistency in environment or routine change
Other
Thirst or hunger
Drug or
Alcohol
use
Caffeine
Approach
Gene
ral
Excluding medical causes is critical (see above)
Ask care givers which they believe is likely causative (see list below)
Cohen-Mansfield
Agitation
Inventory (CMAI)
http://www.dementia-assessment.com.au/symptoms/CMAI_Scale.pdf
Distinguishes between the four general categories above to help direct management
Can be used to monitor for treatment efficacy
Categories of behavior changes causes
Psychosis
Presents with
Delusion
s or
Hallucination
s
Fear and distress from
Psychosis
responds to
Atypical Antipsychotic
s (e.g.
Risperidone
,
Quetiapine
)
Avoid
Antipsychotic
s (except
Quetiapine
) in
Lewy Body Dementia
(paradoxically worsen)
Avoid
Antipsychotic
s as
Chemical Restraint
only
Mood
Presents with dysphoria, screaming
Consider Cornell Scale for depression assessment in
Dementia
Non-pharmacologic therapy is most effective
Consider
Bupropion
or
Methylphenidate
to assist with withdrawn patients
Consider ECT for severely withdrawn or disruptive behaviors
Consider
Mirtazapine
for suppressed appetite
Physical behaviors (overstimulation response)
Presents with hitting or other
Violent Behavior
s
Always consider pain as an underlying cause of physical behaviors
Consider
Olanzapine
(
Zyprexa
,
Zydis
) dissolvable tablet as needed for
Violent Behavior
s
Avoid
Benzodiazepine
s (due to paradoxical worsening)
Disinhibition (understimulation response)
Presents with calling for help, ruminating, voiding in wrong place...
Reorientation activities may help
References
Tung (2012) Mayo POIM Conference, Rochester
Approach
Catastrophic Reaction
Results from Task failure
Patient told that they're wrong
Symptoms
Irritability
Accusation
Tearful
Combative
Management: Non-Pharmacologic
See
No-fail Environment in Dementia
(
Calming Measures in Dementia
)
Approach
Reaction to physical Care
Occurs particularly in
Frontal Lobe
Impairment
Patients Akinetic
Patient wants to be left alone
Management: Non-Pharmacologic
Limit goals (e.g. bath less often)
Follow strict routine at patient's best time of day
Use slow gentle movements in physical care
Approach patient from side or rear
Reassure ("As soon as we're done, I'll stop")
Approach
Screaming
Often no purpose
Associated with non-directed
Agitation
Cause may be multifactorial
Pain
Sensory deprivation
Restraints
Depression in Dementia
Treat possible underlying causes
Aggression-Specific Types/Other Causes
Disinhibition
Agitated depression
Precautions
Antipsychotic
s only demonstrate benefit in anger, aggression and paranoia
No benefit in quality of life, care needs, or functional capacity
Atypical Antipsychotic
s have serious, including life-threatening side-effects
Atypical Antipsychotic
s in older patients with
Dementia
are associated with a two fold increased mortality
Adverse effects include
QT Prolongation
, aspiration risk and gait disturbance and increased
Fall Risk
Obtain
Informed Consent
before starting
Medication risks and benefits should be reviewed with patients and their care
Caregiver
s before starting
Avoid using newer agents without proven efficacy and longterm safety (and very expensive)
Example: Nuedexta (
Dextromethorphan
/
Quinidine
) -
NMDA Receptor Blocker
(2017) Presc Lett 24(6): 33
References
Sultzer (2008) Am J Psychiatry 165(7): 844-54 [PubMed]
Gill (2007) Ann Intern Med 146(11): 775-86 [PubMed]
Management
Medications
Indications
Failed
Behavior Modification
as above (see
Calming Measures in Dementia
)
Severe and refractory
Agitation
Medication preparations
Approach
Start dosing at one third to one half of typical starting dose
Titrate slowly and taper off if no effect within first 4 weeks
Even if effective, attempt to taper after 4 months (often can taper without relapse)
Antipsychotic
s (all agents with similar efficacy)
Atypical Antipsychotic
s with low
Extrapyramidal Effect
s (but overall preferred by geriatricians)
Use caution
Increased risk of death on
Atypical Antipsychotic
s
Obtain baseline EKG before starting to check
QT Prolongation
Aripiprazole
(
Abilify
)
Consistently effective with small reductions in adverse behaviors
Lower daily doses (<10 mg) are effective
Increased CV and CVA risk, but unknown effect on mortality
Risperidone
(
Risperdal
) 0.5 mg orally twice daily ($78/month)
Effective for
Psychosis Symptoms
Side effects may limit use
As with
Quetiapine
and
Olanzapine
, had a 3.5% absolute increase in mortality
Quetiapine
(
Seroquel
) 25 mg orally twice daily ($85/month)
Preferred of the
Atypical Antipsychotic
s in
Parkinson's Disease
,
Lewy Body Dementia
As with
Risperdal
and
Olanzapine
, had a 3.5% absolute increase in mortality
Atypical Antipsychotic
s that are FDA approved for Agitation in Dementia (but very expensive as of 2023)
Brexpiprazole
Moderately reduced
Agitation
and well tolerated at 12 weeks
Lee (2023) JAMA Neurol 80(12): 1307-16 [PubMed]
Old, cheap drugs with high
Extrapyramidal Effect
s
Haloperidol
0.5 mg orally twice daily ($5/month)
Useful as initial agent in acute
Agitation
Switch to agent below if need to continue
Avoid in
Parkinson's Disease
Markedly impairs mobility secondary to rigidity
Agents to avoid due to low efficacy
Olanzapine
(
Zyprexa
) was associated with worse functional outcomes
Sultzer (2008) Am J Psychiatry 165(7): 844-54 [PubMed]
Ziprasidone
(
Geodon
)
Paliperidone
(
Invega
)
Clozapine
(
Clozaril
)
Asenapine
(
Saphris
)
Iloperidone
(
Fanapt
)
Other agents with potential benefit
Divalproex
(
Depakote
)
Carbamazepine
(
Tegretol
) titrate to 300 mg/day
Limited by sedation, narrow therapeutic window
Trazodone
(
Desyrel
) 50 mg PO qhs
Selective Serotonin Reuptake Inhibitor
Consider as a first-line agent, and taper off if no effect at 2 to 3 months
Escitalopram
(
Lexapro
) up to 10 mg orally daily
Preferred over
Celexa
with generic status in 2012 and no known
QT Prolongation
Sertraline
(
Zoloft
)
Mirtazapine
(
Remeron
)
Miscellaneous
Antidepressant
s
Bupropion
Newer
Tricyclic Antidepressant
s (e.g.
Pamelor
)
Agents with only anecdotal support
Beta Blocker
s (e.g.
Propranolol
)
Lithium
Buspirone
(
Buspar
)
Agents to use with only with caution
Benzodiazepine
s (e.g.
Lorazepam
(
Ativan
) 0.25 - 0.50 mg)
Give 30 minutes prior to physical care
May cause
Ataxia
, risk of falls,
Delirium
and paradoxical worsening
Consider scheduled
Acetaminophen
instead
Avoid agents lacking safety and efficacy data
Avoid Nuedexta (
Dextromethorphan
/
Quinidine
)
Avoid
Nuplazid
(
Pimavanserin
)
References
(2022) Presc Lett 29(6): 33
Howell in Duthie (1998)
Geriatrics
p. 295-305
Ham (1997) Postgrad Med 101(6):57-70 [PubMed]
Reese (2016) Am Fam Physician 94(4): 276-82 [PubMed]
Stewert (1995) Am Fam Physician 52(8):2311-22 [PubMed]
Type your search phrase here